DCTH - Delcath Systems, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
7.21
-1.47 (-16.94%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close8.68
Open8.88
Bid0.00 x 0
Ask0.00 x 0
Day's Range7.21 - 10.20
52 Week Range1.22 - 14,261.60
Volume244,236
Avg. Volume26,832
Market Cap6.721M
Beta-1.82
PE Ratio (TTM)N/A
EPS (TTM)-79.64
Earnings DateMar 23, 2017 - Mar 24, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.00
Trade prices are not sourced from all markets
  • GlobeNewswire8 days ago

    Delcath Reminds Shareholders that the Rights Offering Subscription Period Expires Wednesday, September 26, 2018

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, reminds its shareholders of the expiration on Wednesday September 26, 2018. The subscription rights will be exercisable until 5:00 p.m. Eastern time on September 26, 2018, though most broker dealers will require holders of rights to exercise in advance of this date. Under the terms of the rights offering, Delcath distributed, at no charge, non-transferable subscription rights to purchase 500 shares of its common stock to holders of record for each share of common stock held on the record date, and to holders of its warrants to purchase common stock.

  • GlobeNewswire17 days ago

    Multi-center Analysis of Outcomes Data on Use of Delcath CHEMOSAT in the Treatment of ICC to be Published in European Radiology

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the result of a multicenter analysis of outcomes in patients with intrahepatic cholangiocarcinoma (ICC) treated with CHEMOSAT has been accepted for publication in the journal European Radiology. The retrospective analysis—Percutaneous Hepatic Perfusion (Chemosaturation) with Melphalan in Patients with Intrahepatic Cholangiocarcinoma: European Multicenter Study on Safety, Short Term Effects and Survival—was conducted by investigators in Germany, Italy, Netherlands, Spain and France.  The results have been previously presented to a Delcath sponsored Key Opinion Leaders forum, where investigators agreed the data "demonstrate an efficacy signal in ICC and is worthy of full clinical investigation." A summary of these findings was later presented to the Cholangiocarcinoma Foundation 2017 annual meeting and have provided a basis for the protocol design for the Company’s registration trial in ICC, which has commenced.  Data from this analysis is embargoed until publication.

  • GlobeNewswire24 days ago

    Delcath Announces Extension of Rights Offering Period to September 26, 2018

    Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that it has completed the initial rights offering period and will be extending for an additional 30-day period, until 5:00 PM Eastern time on September 26, 2018. Delcath Systems, Inc. is an interventional oncology Company focused on the treatment of primary and metastatic liver cancers. Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S.  In Europe, our system has been commercially available since 2012 under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT), where it has been used at major medical centers to treat a wide range of cancers of the liver.

  • GlobeNewswire25 days ago

    Delcath Announces Acceptance of Abstract for Poster Presentation at CIRSE 2018

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces an abstract from a study conducted in Germany of the use of the Delcath Hepatic CHEMOSAT® Delivery System to treat patients with metastatic ocular melanoma with liver metastases, has been accepted for presentation as a poster at the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) annual meeting. The abstract, Survival and Response of Patients with Metastatic Ocular Melanoma after Chemosaturation Percutaneous Hepatic Perfusion, will be presented by M. Zeile, and A. Stang, et al of the Asklepios Barmbek Clinic in Hamburg, Germany.

  • GlobeNewswire29 days ago

    Delcath Announces 3rd Independent Safety Review of Randomized Trial Data for Metastatic Ocular Melanoma; Recommended Continuation with no Trial Modification

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the independent Data Safety Monitoring Board (DSMB) of the Phase 3 clinical trial for Patients with Hepatic Dominant Ocular Melanoma (The FOCUS Trial) completed another pre-specified review of safety data for treated patients in the trial. This review was conducted on data collected from the prior randomized protocol for the FOCUS Trial.

  • GlobeNewswirelast month

    Delcath Announces Pending Expiration to Rights Offering Subscription Period

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, reminds its shareholders of the initial expiration, on Monday August 27, 2018, of the subscription period for its previously announced rights offering that began on Tuesday, August 7, 2018.  The Company also reminds holders of rights that most broker/dealers require clients to place orders in advance of the official expiration date of August 27, 2018 so that holders of rights should confirm with their broker/dealers directly in order to enable timely participation. Under the terms of the rights offering, Delcath distributed, at no charge, non-transferable subscription rights to purchase 500 shares of its common stock to holders of record for each share of common stock held on the record date, and to holders of its warrants to purchase common stock.

  • GlobeNewswirelast month

    First Patient Enrolled in Delcath Amended Registration Trial in Metastatic Ocular Melanoma

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the first patient has been enrolled under the amended protocol for its registration trial in ocular melanoma liver metastases. The trial, A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma (The FOCUS Trial), will enroll a minimum of 80 patients with ocular melanoma metastatic to the liver. “We are very pleased that the team at Stanford were able to begin enrolling patients in the amended trial so quickly,” said Jennifer K. Simpson, PhD, MSN, CRNP, President and Chief Executive Officer of Delcath Systems.

  • GlobeNewswirelast month

    Delcath Announces Beginning of Enrollment of Amended Metastatic Ocular Melanoma Registration Trial

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that patient enrollment has begun under the amended protocol for its registration trial in ocular melanoma liver metastases. Stanford University Medical Center is the first trial site to obtain Institutional Review Board (IRB) approval for the amended protocol and the center is open to patient enrollment.

  • GlobeNewswirelast month

    Delcath Issues Letter to Stockholders

    Delcath Systems, Inc. (DCTH) (“Delcath” or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer, has issued a Letter to Stockholders providing a business update. The full text of the Letter, which has also been posted to the Company's website, is as follows. The steps we announced recently are the result of many months of behind the scenes work with the FDA and are intended to significantly reduce the time to submission of a New Drug Application (NDA) in the ocular melanoma indication, to provide this critical therapy to patients in a more timely manner and to fully realize the commercial potential of our PHP® Therapy.  I write to you today to discuss what these steps mean for our shared future and why we believe they can lead to shareholder value.

  • GlobeNewswirelast month

    Delcath Announces Second Quarter Fiscal 2018 Financial Results

    NEW YORK, Aug. 15, 2018-- Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces financial results for the quarter ended June ...

  • GlobeNewswire2 months ago

    Delcath Announces Commencement of Rights Offering Subscription Period

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces the subscription period for its previously announced rights offering begins on Tuesday, August 7, 2018 (upon declaration of effectiveness of its registration statement on Form S-1 by the SEC). Under the terms of the rights offering, Delcath distributed, at no charge, non-transferable subscription rights to purchase 500 shares of its common stock to holders of record for each share of common stock held on the record date, and to holders of its warrants to purchase common stock. Each basic subscription right will entitle the holder of record to purchase 500 shares of common stock at the subscription price of $1.75 per share.

  • GlobeNewswire2 months ago

    Summary of Calendar for Upcoming Proposed Delcath Rights Offering

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, reminds investors that the ownership date cutoff for the Company’s upcoming rights offering is August 1, 2018 at 4 P.M. Eastern Time.  The Company previously filed a registration statement with the SEC for the sale of up to 28,571,429 shares of common stock at a subscription price of $1.75 per share. The offering will only be made upon the registration statement being declared effective by the SEC.  The rights offering would also allow the Company’s Board of Directors, officers and employees to participate on the same terms as other shareholders in the Company, and the entire board and members of the Company’s management team have indicated an intent to participate.

  • GlobeNewswire2 months ago

    Delcath Amends Phase 3 Ocular Melanoma Trial Protocol

    NEW YORK, July 27, 2018 (GLOBE NEWSWIRE) --  Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company has filed an amendment with the U.S. Food & Drug Administration to revise the protocol for its Phase 3 clinical trial in ocular melanoma liver metastases. Under the terms of the amendment, the trial, now entitled, A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma, will enroll 80 patients with ocular melanoma metastatic to the liver.

  • GlobeNewswire2 months ago

    Delcath Systems Announces Rights Offering and Backstop Commitment Ownership Date of August 1, 2018

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that it has filed a registration statement on Form S-1 with the SEC for a rights offering for up to 28,571,429 shares of common stock at the subscription price of $1.75 per share. Under the terms of the rights offering, on August 3, 2018, Delcath expects to distribute, at no charge, 500 non-transferable subscription rights to purchase shares of its common stock to holders of record for each share of common stock held on the record date, and to holders of its warrants to purchase common stock held on the Ownership Date, as of 4:00 p.m., Eastern time, on Wednesday, August 1, 2018.

  • GlobeNewswire2 months ago

    Delcath Announces 100th Commercial CHEMOSAT Treatment Completed at Leiden University Medical Center, The Netherlands

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that physicians at Leiden University Medical Center (LUMC) in the Netherlands, led by Dr. Mark C. Burgmans, completed their 100th treatment with PHP® Therapy using the company’s Hepatic CHEMOSAT® Delivery System (CHEMOSAT). Percutaneous Hepatic Perfusion (PHP) Therapy with Melphalan/HDS was developed by Delcath Systems as a targeted, whole organ therapy for the liver.